Compare QDEL & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | VCEL |
|---|---|---|
| Founded | 1979 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 1997 |
| Metric | QDEL | VCEL |
|---|---|---|
| Price | $28.38 | $34.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $40.00 | ★ $57.50 |
| AVG Volume (30 Days) | ★ 1.0M | 437.6K |
| Earning Date | 02-11-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $2,730,200,000.00 | $258,716,999.00 |
| Revenue This Year | N/A | $18.02 |
| Revenue Next Year | $2.28 | $18.52 |
| P/E Ratio | ★ N/A | $140.42 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $19.50 | $29.24 |
| 52 Week High | $43.92 | $58.77 |
| Indicator | QDEL | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 39.55 |
| Support Level | $27.75 | $34.83 |
| Resistance Level | $30.50 | $36.56 |
| Average True Range (ATR) | 1.50 | 1.61 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 56.50 | 10.66 |
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.